Abstract: RNA-based drugs are emerging as a promising treatment for a number of diseases, including SARS-CoV-2. However, delivery vehicles that efficiently deliver RNA-based drugs are often limited to the liver, necessitating the optimization and discovery of new non-liver delivery vehicles. In this talk, I will discuss our pipeline for the identification of lipid nanoparticle (LNP)-based delivery vehicles, such as LNPs currently used by Pfizer and Moderna.
Bio: Kalina Paunovska is a postdoctoral scholar in the Georgia Tech Department of Biomedical Engineering. She was an NIH T‐32 fellow. She received her Ph.D. degree in biomedical engineering from the Georgia Tech and Emory, Atlanta, Georgia, in 2020. She received her B.S. degree in biomedical engineering from the University of Miami, Coral Gables, Florida, in 2016. Her research focuses on investigating the biological mechanisms that drive LNP delivery to different cell types, and the integration of next‐generation sequencing technologies with drug delivery.
]]>